HIV-1 Vpu restricts Fc-mediated effector functions in vivo

HIV-1 Vpu在体内限制Fc介导的效应功能

阅读:5
作者:Jérémie Prévost ,Sai Priya Anand ,Jyothi Krishnaswamy Rajashekar ,Li Zhu ,Jonathan Richard ,Guillaume Goyette ,Halima Medjahed ,Gabrielle Gendron-Lepage ,Hung-Ching Chen ,Yaozong Chen ,Joshua A Horwitz ,Michael W Grunst ,Susan Zolla-Pazner ,Barton F Haynes ,Dennis R Burton ,Richard A Flavell ,Frank Kirchhoff ,Beatrice H Hahn ,Amos B Smith 3rd ,Marzena Pazgier ,Michel C Nussenzweig ,Priti Kumar ,Andrés Finzi

Abstract

Non-neutralizing antibodies (nnAbs) can eliminate HIV-1-infected cells via antibody-dependent cellular cytotoxicity (ADCC) and were identified as a correlate of protection in the RV144 vaccine trial. Fc-mediated effector functions of nnAbs were recently shown to alter the course of HIV-1 infection in vivo using a vpu-defective virus. Since Vpu is known to downregulate cell-surface CD4, which triggers conformational changes in the viral envelope glycoprotein (Env), we ask whether the lack of Vpu expression was linked to the observed nnAbs activity. We find that restoring Vpu expression greatly reduces nnAb recognition of infected cells, rendering them resistant to ADCC. Moreover, administration of nnAbs in humanized mice reduces viral loads only in animals infected with a vpu-defective but not with a wild-type virus. CD4-mimetics administration, known to "open" Env and expose nnAb epitopes, renders wild-type viruses sensitive to nnAbs Fc-effector functions. This work highlights the importance of Vpu-mediated evasion of humoral responses.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。